107188-74-9

Usage

Uses

Used in Pharmaceutical Industry:
FLB 457 is used as an intermediate in the synthesis of FLB 457 Hydrobromide for its potential application as an antipsychotic agent. The compound's antidopaminergic properties make it a promising candidate for the development of new treatments for various psychiatric disorders.
Used in Research and Development:
In the field of medicinal chemistry and neuroscience, FLB 457 serves as a valuable research compound for understanding the mechanisms of action and potential therapeutic effects of antipsychotic drugs. Its use in research can contribute to the advancement of knowledge in the treatment of psychiatric conditions and the development of novel pharmaceuticals.

Upstream product

• 107188-91-0 5-bromo-2,3-dimethoxybenzoic acid chloride 
• 22795-99-9 (S)-2-(Aminomethyl)-1-ethylpyrrolidine 
• 72517-23-8 5-bromo-2,3-dimethoxybenzoic acid 
• 5034-74-2 5-bromo-3-methoxysalicylaldehyde 
• 71295-21-1 5-bromo-2,3-dimethoxybenzaldehyde 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 

Downstream Products

• 107188-88-5 (-)-(S)-N-<(1-Ethylpyrrolidin-2-yl)methyl>-2,3-dimethoxy-5-(trimethylsilyl)benzamide 
• 107188-87-4 epidepride 
• 107188-81-8 (-)-(S)-N-<(1-ethyl-2-pyrrolidinyl)methyl>-2,3-dimethoxybenzamide 

Relevant academic research and scientific papers

Pyrrolidine compounds, salts thereof, applications of compounds or salts thereof in nuclear magnetic probes and medicines, reagent, and medicine

The invention provides pyrrolidine compounds, salts thereof, applications of the compounds or the salts thereof in nuclear magnetic probes and medicines, a reagent, and a medicine. The benzamide methylpyrrolidine compounds have a chemical structure represented by general formula (I); and in the formula (I), R is selected from a methyl group, an ethyl group, a methoxy group, an ethoxy group and halogen, R is selected from a methyl group, an ethyl group, a methoxy group, an ethoxy group and halogen, R is selected from C1-5 alkyl groups and H, X is selected from C1-10 alkylene groups or is deleted, X is selected from -(CH2CH2O)n- (n is 1-5) or is deleted, X is selected from C1-5 alkyl groups, X is selected from oxygen, sulfur and a methylene group, and Ln is selected from Gd and Eu. The compounds have a gadolinium and europium chelating structure formed by combining with a dopamine D2 receptor and depending on intramolecular chelating groups, and specifically enhance the contrast of dopamine D2 receptor expression tissues on images in magnetic resonance imaging.

Improved specific radioactivity of the PET radioligand [11C]FLB 457 by use of the GE Medical Systems PETtrace MeI MicroLab

[11C]FLB 457 is a high affinity dopamine D2 receptor radioligand that is used for visualisation and quantitation of extrastriatal dopamine D2 receptors with positron emission tomography (PET). In this study, we report a co

Facile preparation of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3-dimethoxy-5- (tributyltin)benzamide from isoremoxipiride: The precursor of [125I]- and [123I]epidepride

[125I]Epidepride, (S)-(-)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo-2,3- dimethoxybenzamide ([125I]NCQ 219), is a new, extremely potent radioligand, useful in the study of the distribution of the dopamine D-2 recepto

Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study

(S)-5-Bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide (6) and some related compounds, i.e. the R isomer 7, the 3-hydroxy analogue 8, the desbromo derivative 9, the monomethoxy compound 10, and the 2,4-dimethoxy analogue 11, have been synth